Tailoring Treatment Decision-making in Metastatic Breast Cancer prototype of selective oestrogen receptor modulators (SERMs). It saturates the nuclear ER, blocks the interaction of estrogen with ER and stops the ER-dependent growth of BC cells. It is used orally at a dosage of 20mg per day. Tamoxifen has agonist effects that produce undesirable side effects such as uterine cancer, and favourable side effects such as increased bone density. Toremifene is another SERM that is effective in ER-positive MBC, but it was found to be crossresistant to tamoxifen and did not gain clinical recognition. 19 Fulvestrant, a pure anti-oestrogen, is a selective oestrogen receptor downregulator (SERD) that destroys ERs and decreases the number of PRs in BC cells. 20 Fulvestrant is now approved for tamoxifen-resistant tumours. It was equivalent to the steroidal aromatase inhibitor (AI) exemestene after failure of non-steroidal AIs (anastrozole and letrozole) where median time to progression (TTP) in both exemestene and fulvestrant was 3.7 months. 21 
Aromatase Inhibitors
Aminogluthetimide (AG) is a first-generation AI that has replaced surgical adrenalectomy. 22 AG is a non-specific AI that suppresses steroidogenesis. Patients receiving it require supplementation of corticosteroids. AIs interfere with peripheral conversion of androstenedione into oestrogens, thus suppressing the sources of oestrogen in the post-menopausal woman. AIs have been shown to be effective in tamoxifen-resistant patients. Anastrozole was shown to produce lesser toxicity and equivalent 56% response rates to tamoxifen. 23, 24 Letrozole showed a higher overall objective response of 32 versus 21%, with a clinical benefit of 49 versus 38% and an overall survival of 34 versus 30 months for tamoxifen. 25 Exemestene gives 23% response rate after progression on tamoxifen. 26 AIs gave better results when compared with megesterol acetate. [27] [28] [29] AIs are now recommended as first-line HT in post-menopausal women. To be effective, AIs have to induce marked suppression of oestrogens of over 90%. Letrozole has been shown to produce more significant aromatase inhibition. No clinical study has yet shown definite superiority of one agent over the other. Results of an ongoing clinical trial comparing the three agents will be known in a few years' time. 30 After failing to respond to one agent, patients may be switched to another one. The
Evaluation of Faslodex versus Exemestane Clinical Trial (EFECT) has
recently shown that after progression on a non-steroidal AI (anstrozole or letrozole), the steroidal AI exemestene produces clinical benefit (31.5%) and response rates (6.7%) that are equivalent to fulvestrant (32.2 and 7.4%, respectively). 21 
Progestational Agents
Progestational agents have also been used after failing to respond to tamoxifen. Synthetic megesterol acetate is the most commonly used agent (dosages of 40mg four times daily) and produced response rates in the study, which compared it with exemestene. 27 Megesterol acetate is used after failing to respond to tamoxifen and AIs.
Tailoring Hormone Therapy of Metastatic Breast Cancer in

Pre-menopausal Patients
HT is used as a first-line therapy in pre-menopausal women with nonvisceral or low-bulk soft-tissue and bone MBC. Ovarian ablation/ ovarian suppression (OA/OS) may be achieved by either surgical oophorectomy or irradiation. Patients are usually given tamoxifen in addition to OA/OS. OS is also achieved with a luteinising-hormonereleasing hormone (LHRH) such as goserelin (Zoladex, Leuprolide or Triptorelin). The combination of LHRH with tamoxifen is better than tamoxifen alone, with an overall survival of 2.9 versus 2.5 years. 31 Recent small series have indicated that OA/OS can be successfully combined with AIs in pre-menopausal women with HR-positive MBC, 32 and a recent phase II study of 45 patients showed a 72% clinical benefit (CR: 3% + PR: 34% + stable disease over 6 months: 34%), median TTP of 8 months (range two to 63 months) and median overall survival of 26 months (11 to more than 63 months) with combined overall survival and AI modality. 33 
Tailoring Chemotherapy for Metastatic Breast Cancer
BC is generally considered a chemotherapy-sensitive tumour.
Chemotherapy is generally used upfront in patients with negative HRs, hormone-refractory disease and in the presence of rapidly proliferating and advancing disease, visceral disease, high-volume and multiple-site metastasis in patients with positive HRs. Chemotherapy is generally used at regular intervals and cycles that would cause maximal cell kill with limited reversible toxicity on normal tissues. Recent data indicate that low-dose daily or weekly metronomic chemotherapy may have additional antiangiogenic mechanisms of action. 34 Most effective agents include anthracyclines and taxanes, which give 60-70% response rates. Other effective agents include fluorouracil, capecitabine, vinorelbine, cyclophosphamide, gemcitabine and platinum salts. 35, 36 Taxanes are useful in patients who have tumours that are resistant to anthracyclines. 37 Recent data show that weekly paclitaxel is better than a three-weekly regimen and it is recommended to be used as such. 38 Newer taxanes include nanoparticle-albuminbound paclitaxel (nab-paclitaxel: Abraxane), which produces higher response rates than paclitaxel (33 versus 19%) . It has no hypersensitivity reactions but induces more neuropathy. 40 
Combination versus Sequential Use of Chemotherapy in
Metastatic Breast Cancer
Combination chemotherapy includes fluorouracil plus doxorubicin plus cyclophosphamide, cyclophosphamide plus epirubicin plus fluorouracil, doxorubicin plus cyclophosphamide (AC) or epirubicin plus cyclophosphamide (EC), doxorubicin plus docetaxel or doxorubicin plus paclitxel (AT). Combination AT versus AC was studied and no survival advantage noted. 41 Taxanes combined with doxorubicin 42 showed a longer TTP. Docetaxel combined with adriamycin and cyclophosphamide gave more significant toxicity. 43 On the other hand, significant overall response rate (ORR) (42 versus 30%), TTP 6.1 versus 4.2 months and overall survival advantage of 14.5 versus 11.5 months was reported with the combination of docetaxel plus capecitabine versus docetaxel as a single agent. 44 Another approved combination is gemcitabine plus paclitaxel, which produced a significantly higher ORR of 40.8 versus 22.2%, TTP 5.2 versus 2.9 months and overall survival of 18.5 versus 15.8 months versus single-agent paclitaxel in a phase III trial. 45 Gemcitabine combined with vinorelbine compared with single-agent vinorelbine in a phase III study of patients refractory to anthracyclines and taxanes with heavy visceral disease showed a non-statistically significant ORR of 36 versus 26% and significant PFS of six versus four months, but with a higher haematological toxicity. 46 Vinorelbine is an effective agent in MBC and has been combined with cisplatin in phase II studies. 47 Platinum compounds are getting more attention for triplenegative disease. However, no definite data are yet available. The Breast Cancer combination of ixabepilone (Ixempra), a new semi-synthetic epothilone analogue with capecitabine, produced 35 versus 14% objective response rates in heavily pre-treated patients progressing after anthyracyclines and taxanes, 48 and is now approved for use in patients with anthracycline and taxane-resistant tumours.
Although combination chemotherapy is generally more active and produces higher response rates and longer TTP, most patients receiving single-agent chemotherapy use other drugs after progression, and most studies did not have a planned cross-over analysis. Such a study comparing anthracyclines with taxanes in combination or in sequence did not show an improvement of TTP or survival. 49 Combinations are used more in younger patients, who have a better tolerance than older patients, in the presence of a more aggressive disease and for more bulky visceral involvement. Otherwise, sequential administration of drugs, particularly anthracycline and taxanes, is preferred.
Tailoring Duration of Chemotherapy to Response and Toxicity in Metastatic Breast Cancer
Patients are usually evaluated for the palliation and disappearance of symptoms and signs of disease, as well as tumour markers and imaging studies. If the patient shows improvement after two to three cycles of a certain chemotherapy regimen, it is continued for a total of six to eight cycles. The exact total duration of therapy depends on the response and toxicity profile of the drugs used. Anthracyclines are limited by potential cardiotoxicity. Dexrazoxane, an iron chelator, has been shown to reduce anthracycline-related cardiac toxicity 50 and is approved for patients receiving more than 300mg/m 2 of doxorubicin.
Pegylated doxorubicin has similar results to doxorubicin for ORR, PFS and overall survival and produced less cardiac toxicity than doxorubicin. 51 There are no data to show advantages for maintenance chemotherapy and it is generally not recommended. Once patients complete their planned and tolerable therapy they are placed under observation if they have negative HRs, or placed on HT if they have positive HRs. Duration of targeted therapy is discussed below.
Targeted Therapy in Metastatic Breast Cancer
Patients with MBC whose tumours show overexpression of HER2/neu cell surface receptors by IHC+++, or who have amplification of the corresponding HER2 gene when HER2/neu is borderline by IHC (two plus), benefit from anti-HER2-targeted therapy. Trastuzumab is a new humanised monoclonal antibody that targets the extracellular domain of HER2 cell surface receptors and gives 17% ORR in MBC. It has been shown to result in prolonged overall survival as a first-line therapy for MBC patients. 52 Trastuzumab is more effective when used in combination chemotherapy with anthracyclines, cyclophosphamide and taxanes, and gives an added survival advantage over chemotherapy. [52] [53] [54] Combination treatment with chemotherapy is preferred over trastuzumab monotherapy because of a higher response rate, reaching 60-70% for the combination 55 compared with 20-30% for monotherapy. 56, 57 Excessive cardiac toxicity was noted when used with anthracycline, 58, 59 and concurrent use of trastuzumab with anthracycline is avoided. Trastuzumab is more safely combined with taxanes. 60 
Lapatinib
Lapatinib is an oral 4-anilinoquinazoline derivative and a reversible dual tyrosine kinase inhibitor that affects HER1 and HER2/ErbB2. 63 Trastuzumab-resistant HER2-positive cells may remain sensitive to lapatinib. Combining lapatinib with anti-HER2 antibodies may produce synergistic effects and enhance apoptosis in BC cells with Her-2 overexpression in different studies. 64 Lapatinib combined with capecitabine was associated with a 51% reduction in the risk of disease progression and a median PFS time of 37 weeks, compared with 18 weeks in the capecitabine single-agent arm. ORR for the combination therapy group was 23% compared with 14% in the monotherapy group (p=0.113). The combination therapy group had a tendency to experience fewer progressive central nervous system (CNS) metastases (11 versus four). Lapatinib is a small molecule that crosses into the cerebrospinal fluid. The effect in reducing CNS metastases has been shown in another phase II trial. 65 Lapatinib is now approved for use in trastuzumab-resistant patients and is being investigated for first-line therapy. 
Pertuzumab
